Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer by A. A. Tryakin, P. A. Balunov

Subjects: Get full text

Pharmacoeconomic aspects of the diabetic ketoacidosis prevention in type 1 diabetes mellitus by self-monitoring of blood ketones by E. E. Petryaykina, D. Yu. Belousov, I. I. Rybkina, I. E. Koltunov

“…Objective: To evaluate the epidemiology of the DKA and pharmacoeconomic aspects of monitoring blood ketones at home, as one of the measures of prevention of diabetic ketoacidosis in patients with type 1 diabetes in Russia. …”
Get full text

Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin

“…In carrying out the pharmacoeconomic analysis itself, a cost-effectiveness analysis (CEA) was applied with the calculation of the corresponding cost-effectiveness ratio (CER), incremental cost-effectiveness ratio (ICER) according to the formula, as well as an a «budget impact analysis». …”
Get full text

Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective by Luciana Saboya Brito Dal Col, Danilo L. Andrade, Lucas M. Gon, Diego M. Capibaribe, Marcelo P. Amaro, Natássia C. C. Truzzi, Barbara R. Malkomes, Leonardo O. Reis

Get full text

Pharmacoeconomic evaluation of stroke and myocardial infarction prevention in hypertensive patients: Markov model based on the ACCOMPLISH trial by Aozi Feng, Weizhao Lin, Li Li, Mengnan Zeng, Jun Lyu

“…Objective We evaluated the pharmacoeconomics of amlodipine combined with benazepril and hydrochlorothiazide combined with benazepril in the treatment of hypertension using a Markov model to provide an evidence-based reference for clinical drug use. …”
Get full text

Imaginary Worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 2015 by Paul C Langley

Subjects: “…cost-effectiveness modeling, credibility, imaginary worlds, scientific method, PharmacoEconomics journal…”
Get full text

Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study by Mangesh P Kamath, K C Lakshmaiah, K Govind Babu, D Loknatha, Linu A Jacob, Suresh MC Babu

Subjects: Get full text

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer by A S Kolbin, I A Vilyum, M A Proskurin, Yu E Balikina, A V Pavlysh

“…To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in the Russian healthcare system. …”
Get full text

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+ by Viola Sacchi

“…Gefitinib is a selective inhibitor of the EGFR tyrosine kinase and is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK. From the pharmacoeconomic point of view gefitinib is dominant (more effective and less expensive) compared to the alternatives. …”
Get full text

Dehospitalization: pharmacoeconomic aspects and the impacts of days saved from hospitalization in renal transplant patients using carbapenems by Thaynara Carvalho DE FREITAS, João Antonio DE SOUSA, Alene Barros DE OLIVEIRA, Maria Gabrielle LINHARES, Cinthya Cavalcante DE ANDRADE, Evelyne Santana GIRÃO, Henry Pablo REIS

“…Methodology: This is a descriptive and retrospective observational study with a quantitative, characterized as a pharmacoeconomic analysis of cost minimization of the treatment performed with meropenem in patients hospitalized in the renal transplant units of a teaching hospital in the state of Ceará and outpatients who migrated for OPAT with ertapenem in outpatient services. …”
Get full text

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin

Get full text

Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment by François R. Girardin, Karen Cohen, Matthias Schwenkglenks, Matthias Schwenkglenks, Isabelle Durand-Zaleski

Subjects: “…pharmacoeconomics…”
Get full text

Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price by D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov

Get full text

Pharmacoeconomic evaluation of aspirin therapy in pharmaceutical prevention of the first acute myocardial infarction in patients with stable angina by A. Yu. Kulikov, A. V. Kontsevaya

“…Aim. To perform pharmacoeconomic analysis of the standard therapy vs. standard therapy plus enteric-coated aspirin, Aspirin Cardio®, in preventing acute myocardial infarction (AMI) among patients with stable angina (SA). …”
Get full text

The discovery of “sale amarissimo antifebbrile” (“bitter febrifugal saline”) by Bartolommeo Rigatelli, i.e. the origins of pharmacoeconomics by Piero Marson, Giampiero Pasero

Subjects: Get full text

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases by A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy

“…Aim. To conduct a pharmacoeconomic analysis of the use of the drug Eliquis® (apixaban), belonging to direct oral anticoagulants (DOACs), for the treatment and prevention of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), including in patients suffering from cancer disease compared with other anticoagulants. …”
Get full text

Comparative pharmacoeconomic analysis of osteoarthritis treatment with structum TOC \o "1-5" \h \z and chondrolon by O Y Mayko, G G Bagirova

Get full text

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation by S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova

Subjects: Get full text

Updated guidelines of reporting pharmacoeconomics and health technology assessment results from 2022 ISPOR (CHEERS 2022) by M. A. Truuts, A. A. Kurilev, A. S. Kolbin

Get full text

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS by M. V. Protsenko

Subjects: Get full text